SpiderRock Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

SpiderRock Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$408K	Hold	5,800	–	–	0.01%	669
2024 Q2	$478K	Hold	5,800	–	–	0.01%	570
2024 Q1	$486K	Buy	+5,800	New	+$519K	0.01%	529
2023 Q4	–	Hold	0	–	–	–	119
2023 Q3	–	Hold	0	–	–	–	104
2023 Q2	–	Hold	0	–	–	–	86
2023 Q1	–	Hold	0	–	–	–	82
2022 Q4	–	Hold	0	–	–	–	92
2022 Q3	–	Hold	0	–	–	–	86
2022 Q2	–	Hold	0	–	–	–	77
2022 Q1	–	Hold	0	–	–	–	74
2021 Q4	–	Hold	0	–	–	–	80
2021 Q3	–	Hold	0	–	–	–	72
2021 Q2	–	Hold	0	–	–	–	65
2021 Q1	–	Hold	0	–	–	–	65
2020 Q4	–	Hold	0	–	–	–	66
2020 Q3	–	Hold	0	–	–	–	67
2020 Q2	–	Hold	0	–	–	–	65
2020 Q1	–	Hold	0	–	–	–	54
2019 Q4	–	Hold	0	–	–	–	51
2019 Q3	–	Hold	0	–	–	–	23
2019 Q2	–	Hold	0	–	–	–	28
2017 Q2	–	Hold	0	–	-$6K	–	906
2017 Q1	–	Hold	0	–	–	–	939

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

SpiderRock Advisors's BMRN Position: Q3 2024 in Review

SpiderRock Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2024 at 5,815 shares worth $409K. The position accounts for 0.01% of the portfolio, ranked #667.

SpiderRock Advisors first reported a position in BMRN in Q1 2024 and has held it in 3 quarters since. The position peaked at $487K in Q1 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

SpiderRock Advisors held 5,815 shares of BioMarin Pharmaceuticals worth $409K as of Q3 2024.
SpiderRock Advisors left its BioMarin Pharmaceuticals share count unchanged in Q3 2024.
BioMarin Pharmaceuticals made up 0.01% of SpiderRock Advisors's portfolio in Q3 2024, its #667 holding.
SpiderRock Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
SpiderRock Advisors's BioMarin Pharmaceuticals position peaked at $487K in Q1 2024.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.